Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies

• Main Authors: Ying C. Ou (Author), Lucy Liu (Author), Bilal Tariq (Author), Kun Wang (Author), Ashutosh Jindal (Author), Zhiyu Tang (Author), Yuying Gao (Author), Srikumar Sahasranaman (Author)
• Format: Book
• Published: Wiley, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Zanubrutinib is a potent, second‐generation Bruton's tyrosine kinase inhibitor that is currently being investigated in patients with B‐cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of th...